



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on  
March 7, 2003  
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By: Jeanie Brooks

Atty Docket No: 12E-989110US  
Client Ref: G67

JUN 11 2003  
TECH CENTER 1600/2900

RECEIVED

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jagdish Parasrampuria; Maxine B. Yonker;  
Kenneth E. Schwartz; Marc J. Gurwith  
Application No.: 09/526,802

Filed: 3/16/2000

For: **DHEA Composition And Method**

Examiner: Qazi, S.

Art Unit: 1616

**SUPPLEMENTAL RESPONSE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This paper supplements the Amendment filed on December 16, 2002 in response to the Final Office Action dated September 14, 2002. Applicants respectfully request reconsideration of the above-identified application in view of the following remarks and the accompanying Declaration of Dr. Patrick Stahly. The following document(s) is/are enclosed herewith:

- 1) Declaration of Dr. Patrick Stahly (including Exhibits A-J); and
- 2) Curriculum Vitae of Dr. Patrick Stahly.

**REMARKS**

**Status of the Claims.**

Claims 1-10 and 36-39 are pending in the application.

**Declaration Under 37 C.F.R. § 1.132**

The pending claims stand rejected under 35 U.S.C. § 103(a) as allegedly unpatentable over Morales *et al.* (USPN 5,407,927) and Loria *et al.* (US 5,077,284) in combination with Chang *et al.* (J. Pharm. Sci. 84:1169-70 (1995)). Office Action, page 3. As stated in the Amendment filed December 16, 2002:

All of the pending claims recite "dehydroepiandrosterone (DHEA), at least 85% of which is present as the form I polymorph."